Sphera Funds Management LTD. Makes New Investment in enGene Holdings Inc. (NASDAQ:ENGN)

Sphera Funds Management LTD. purchased a new position in shares of enGene Holdings Inc. (NASDAQ:ENGN - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 560,000 shares of the company's stock, valued at approximately $3,724,000. Sphera Funds Management LTD. owned about 1.27% of enGene as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vontobel Holding Ltd. bought a new stake in enGene in the fourth quarter worth about $69,000. Blue Owl Capital Holdings LP raised its position in enGene by 3.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock worth $21,014,000 after acquiring an additional 101,006 shares during the period. Jane Street Group LLC bought a new stake in enGene in the fourth quarter worth about $93,000. Cubist Systematic Strategies LLC raised its position in enGene by 15.7% in the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock worth $102,000 after acquiring an additional 2,080 shares during the period. Finally, Corton Capital Inc. bought a new stake in enGene in the fourth quarter worth about $157,000. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

enGene Price Performance

NASDAQ ENGN traded up $0.46 on Monday, hitting $3.91. The stock had a trading volume of 80,052 shares, compared to its average volume of 131,558. enGene Holdings Inc. has a 52-week low of $2.65 and a 52-week high of $13.28. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The company has a market capitalization of $199.32 million, a price-to-earnings ratio of -6.74 and a beta of -0.36. The firm has a 50-day moving average of $4.18 and a 200-day moving average of $6.06.

Wall Street Analyst Weigh In

ENGN has been the topic of several research reports. JMP Securities reaffirmed a "market outperform" rating and issued a $18.00 price objective on shares of enGene in a research report on Tuesday, April 29th. Morgan Stanley dropped their price target on shares of enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 11th. HC Wainwright restated a "buy" rating and set a $25.00 price target on shares of enGene in a research note on Tuesday, March 11th. UBS Group cut shares of enGene from a "buy" rating to a "neutral" rating and dropped their price target for the company from $34.00 to $7.00 in a research note on Friday, February 14th. Finally, Piper Sandler started coverage on shares of enGene in a research note on Tuesday, February 18th. They set an "overweight" rating and a $26.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, enGene presently has a consensus rating of "Buy" and an average price target of $23.29.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.